Infertility due to endometriosis. Female infertility of other origin
Conditions
Interventions
Intervention 1: The intervention group receives N-acetylcysteine, a potent antioxidant and immune stimulator that is not found in the diet. The medication is administered as two effervescent tablets (
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 42 Years
Inclusion criteria
Inclusion criteria: Participants aged 20–42 years Ultrasonographic diagnosis of endometrioma Serum anti-Müllerian hormone (AMH) levels ranging from 0.7 to 4.5 ng/mL Body mass index (BMI) less than 30
Exclusion criteria
Exclusion criteria: Women with congenital uterine malformations Severe male factor infertility Participants with a history of asthma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of MII oocytes. Timepoint: 6 weeks after taking the drug or placebo. Method of measurement: Microscopic examination of the oocyte by an embryologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Implantation rate. Timepoint: 6 weeks after taking the drug or placebo. Method of measurement: Serum beta HCG.;Clinical pregnancy rate. Timepoint: 6 weeks after taking the drug or placebo. Method of measurement: Uterin Ultrasound.;Number of embryos at the cleavage stage. Timepoint: 6 weeks after taking the drug or placebo. Method of measurement: Microscopic examination of the oocyte by an embryologist.;Number of embryos at the blastocyst stage. Timepoint: 6 weeks after taking the drug or placebo. Method of measurement: Microscopic examination of the oocyte by an embryologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Sedighi
Tehran University of Medical Sciences
Outcome results
None listed